163 related articles for article (PubMed ID: 35642058)
1. YOD1 serves as a potential prognostic biomarker for pancreatic cancer.
Zhang Z; Zhao W; Li Y; Li Y; Cheng H; Zheng L; Sun X; Liu H; Shao R
Cancer Cell Int; 2022 May; 22(1):203. PubMed ID: 35642058
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
Front Genet; 2022; 13():848391. PubMed ID: 35601487
[No Abstract] [Full Text] [Related]
3. Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway.
Park SS; Baek KH
Cancer Cell Int; 2023 Sep; 23(1):209. PubMed ID: 37743467
[TBL] [Abstract][Full Text] [Related]
4. YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity.
Tanji K; Mori F; Miki Y; Utsumi J; Sasaki H; Kakita A; Takahashi H; Wakabayashi K
Neurobiol Dis; 2018 Apr; 112():14-23. PubMed ID: 29330040
[TBL] [Abstract][Full Text] [Related]
5. YOD1 Deubiquitinates NEDD4 Involved in the Hippo Signaling Pathway.
Park JH; Kim SY; Cho HJ; Lee SY; Baek KH
Cell Physiol Biochem; 2020 Jan; 54(1):1-14. PubMed ID: 31916733
[TBL] [Abstract][Full Text] [Related]
6.
Yang Y; Ren L; Li S; Zheng X; Liu J; Li W; Fu W; Wang J; Du G
Transl Cancer Res; 2022 Apr; 11(4):649-668. PubMed ID: 35571651
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
8. miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.
Pei HZ; Peng Z; Zhuang X; Wang X; Lu B; Guo Y; Zhao Y; Zhang D; Xiao Y; Gao T; Yu L; He C; Wu S; Baek SH; Zhao ZJ; Xu X; Chen Y
Cell Death Discov; 2023 Jul; 9(1):249. PubMed ID: 37454155
[TBL] [Abstract][Full Text] [Related]
9. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer.
Yin L; Lu Y; Cao C; Lu Z; Wei J; Zhu X; Chen J; Guo F; Tu M; Xi C; Zhang K; Wu J; Gao W; Jiang K; Miao Y; Li Q; Peng Y
Front Oncol; 2021; 11():832315. PubMed ID: 35155218
[TBL] [Abstract][Full Text] [Related]
10.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
11. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
12. KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.
Li Y; Su Z; Wei B; Liang Z
Int J Gen Med; 2021; 14():2677-2694. PubMed ID: 34188523
[TBL] [Abstract][Full Text] [Related]
13. MiR-4429 suppresses the malignant development of ovarian cancer by targeting YOD1.
Zhu YM; Chen P; Shi L; Zhu T; Chen X
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8722-8730. PubMed ID: 32964960
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma.
Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ
Front Oncol; 2020; 10():606735. PubMed ID: 33604289
[TBL] [Abstract][Full Text] [Related]
15. A Four Autophagy-Related Gene-Based Prognostic Signature for Pancreatic Cancer.
Zhou Q; Chen X; Chen Q; Liu H; Hao L
Crit Rev Eukaryot Gene Expr; 2021; 31(4):89-100. PubMed ID: 34587439
[TBL] [Abstract][Full Text] [Related]
16. YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-κB.
Schimmack G; Schorpp K; Kutzner K; Gehring T; Brenke JK; Hadian K; Krappmann D
Elife; 2017 Feb; 6():. PubMed ID: 28244869
[TBL] [Abstract][Full Text] [Related]
17. PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.
Bao L; Sun K; Zhang X
Channels (Austin); 2021 Dec; 15(1):680-696. PubMed ID: 34796785
[TBL] [Abstract][Full Text] [Related]
18. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
19. SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.
Li T; Yan Z; Wang W; Zhang R; Gan W; Lv S; Zeng Z; Hou Y; Yang M
Front Mol Biosci; 2021; 8():687319. PubMed ID: 34938771
[No Abstract] [Full Text] [Related]
20. An Integrated Pan-Cancer Analysis of ADAMTS12 and Its Potential Implications in Pancreatic Adenocarcinoma.
Song C; Chen J; Zhang C; Dong D
Front Oncol; 2022; 12():849717. PubMed ID: 35280819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
